Cargando…

The Importance of Direct Patient Reporting of Adverse Drug Reactions in the Safety Monitoring Process

All medicinal products authorized in the European Union are subjects of constant drug-safety monitoring processes. It is organized in a pharmacovigilance system that is designed to protect human health and life by the detection, analysis and prevention of adverse drug reactions (ADRs) and other drug...

Descripción completa

Detalles Bibliográficos
Autores principales: Sienkiewicz, Kamila, Burzyńska, Monika, Rydlewska-Liszkowska, Izabela, Sienkiewicz, Jacek, Gaszyńska, Ewelina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8745009/
https://www.ncbi.nlm.nih.gov/pubmed/35010673
http://dx.doi.org/10.3390/ijerph19010413
_version_ 1784630242275491840
author Sienkiewicz, Kamila
Burzyńska, Monika
Rydlewska-Liszkowska, Izabela
Sienkiewicz, Jacek
Gaszyńska, Ewelina
author_facet Sienkiewicz, Kamila
Burzyńska, Monika
Rydlewska-Liszkowska, Izabela
Sienkiewicz, Jacek
Gaszyńska, Ewelina
author_sort Sienkiewicz, Kamila
collection PubMed
description All medicinal products authorized in the European Union are subjects of constant drug-safety monitoring processes. It is organized in a pharmacovigilance system that is designed to protect human health and life by the detection, analysis and prevention of adverse drug reactions (ADRs) and other drug-related problems. The main role of the aforementioned system is to collect and analyze adverse drug reaction reports. Legislation introduced several years ago allowed patients, their legal representatives and caregivers to report adverse drug reactions, which caused them to be an additional source of safety data. This paper presents the analysis of EudraVigilance data related to adverse drug reactions provided by patients, their representatives, as well as those obtained from healthcare professionals related to medicines which belong to M01A anti-inflammatory and antirheumatic products, a non-steroid group. The objective of the study was to identify the changes in the number and structure of adverse reaction reporting after the introduction of pharmacovigilance (PV) obligations in EU. A review of scientific literature was also conducted to assess the differences in adverse reactions reported by patients or their representatives and by healthcare professionals. We also identified other factors which, according to literature review, influenced the number of adverse reaction reports provided by patients. Analysis of data collected from the EudraVigilance showed that from 2011 to 2013 the number of reports made by patients and their caregivers increased by approx. 24 percentage points, and then, from 2014, it constituted around 30% of the total of reported reactions every year, so patient reporting is an important part of pharmacovigilance system and a source of drugs’ safety information throughout their use in healthcare practice. Additionally, there was no interrelationship between the seriousness of reported adverse reactions and the overall number of patient reports when compared to reports form healthcare professionals.
format Online
Article
Text
id pubmed-8745009
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87450092022-01-11 The Importance of Direct Patient Reporting of Adverse Drug Reactions in the Safety Monitoring Process Sienkiewicz, Kamila Burzyńska, Monika Rydlewska-Liszkowska, Izabela Sienkiewicz, Jacek Gaszyńska, Ewelina Int J Environ Res Public Health Article All medicinal products authorized in the European Union are subjects of constant drug-safety monitoring processes. It is organized in a pharmacovigilance system that is designed to protect human health and life by the detection, analysis and prevention of adverse drug reactions (ADRs) and other drug-related problems. The main role of the aforementioned system is to collect and analyze adverse drug reaction reports. Legislation introduced several years ago allowed patients, their legal representatives and caregivers to report adverse drug reactions, which caused them to be an additional source of safety data. This paper presents the analysis of EudraVigilance data related to adverse drug reactions provided by patients, their representatives, as well as those obtained from healthcare professionals related to medicines which belong to M01A anti-inflammatory and antirheumatic products, a non-steroid group. The objective of the study was to identify the changes in the number and structure of adverse reaction reporting after the introduction of pharmacovigilance (PV) obligations in EU. A review of scientific literature was also conducted to assess the differences in adverse reactions reported by patients or their representatives and by healthcare professionals. We also identified other factors which, according to literature review, influenced the number of adverse reaction reports provided by patients. Analysis of data collected from the EudraVigilance showed that from 2011 to 2013 the number of reports made by patients and their caregivers increased by approx. 24 percentage points, and then, from 2014, it constituted around 30% of the total of reported reactions every year, so patient reporting is an important part of pharmacovigilance system and a source of drugs’ safety information throughout their use in healthcare practice. Additionally, there was no interrelationship between the seriousness of reported adverse reactions and the overall number of patient reports when compared to reports form healthcare professionals. MDPI 2021-12-31 /pmc/articles/PMC8745009/ /pubmed/35010673 http://dx.doi.org/10.3390/ijerph19010413 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Sienkiewicz, Kamila
Burzyńska, Monika
Rydlewska-Liszkowska, Izabela
Sienkiewicz, Jacek
Gaszyńska, Ewelina
The Importance of Direct Patient Reporting of Adverse Drug Reactions in the Safety Monitoring Process
title The Importance of Direct Patient Reporting of Adverse Drug Reactions in the Safety Monitoring Process
title_full The Importance of Direct Patient Reporting of Adverse Drug Reactions in the Safety Monitoring Process
title_fullStr The Importance of Direct Patient Reporting of Adverse Drug Reactions in the Safety Monitoring Process
title_full_unstemmed The Importance of Direct Patient Reporting of Adverse Drug Reactions in the Safety Monitoring Process
title_short The Importance of Direct Patient Reporting of Adverse Drug Reactions in the Safety Monitoring Process
title_sort importance of direct patient reporting of adverse drug reactions in the safety monitoring process
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8745009/
https://www.ncbi.nlm.nih.gov/pubmed/35010673
http://dx.doi.org/10.3390/ijerph19010413
work_keys_str_mv AT sienkiewiczkamila theimportanceofdirectpatientreportingofadversedrugreactionsinthesafetymonitoringprocess
AT burzynskamonika theimportanceofdirectpatientreportingofadversedrugreactionsinthesafetymonitoringprocess
AT rydlewskaliszkowskaizabela theimportanceofdirectpatientreportingofadversedrugreactionsinthesafetymonitoringprocess
AT sienkiewiczjacek theimportanceofdirectpatientreportingofadversedrugreactionsinthesafetymonitoringprocess
AT gaszynskaewelina theimportanceofdirectpatientreportingofadversedrugreactionsinthesafetymonitoringprocess
AT sienkiewiczkamila importanceofdirectpatientreportingofadversedrugreactionsinthesafetymonitoringprocess
AT burzynskamonika importanceofdirectpatientreportingofadversedrugreactionsinthesafetymonitoringprocess
AT rydlewskaliszkowskaizabela importanceofdirectpatientreportingofadversedrugreactionsinthesafetymonitoringprocess
AT sienkiewiczjacek importanceofdirectpatientreportingofadversedrugreactionsinthesafetymonitoringprocess
AT gaszynskaewelina importanceofdirectpatientreportingofadversedrugreactionsinthesafetymonitoringprocess